Chemomab Therapeutics (CMMB) Accounts Payables (2017 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Accounts Payables came in at $485000.0 in Q4 2025, down 23.38% YoY from $633000.0 in Q4 2024, and up 150.0% on a QoQ basis from $194000.0 in Q3 2025.
Chemomab Therapeutics (CMMB) Accounts Payables (2017 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 9 years of Accounts Payables data on file, last reported at $485000.0 in Q4 2025.
- Quarterly Accounts Payables fell 23.38% year-over-year to $485000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $485000.0 (down 23.38% YoY) and the FY2025 annual result came in at $485000.0, down 23.38% from the prior year.
- Accounts Payables grew to $485000.0 in Q4 2025, from $194000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $2.3 million in Q2 2023 to a low of $194000.0 in Q3 2025.
- A 5-year average of $1.0 million and a median of $682000.0 in 2023 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2021 — Accounts Payables surged 1336.56% — and 2024, when it tumbled 76.23%.
- Tracing CMMB's Accounts Payables over 5 years: stood at $1.3 million in 2021, then grew by 26.35% to $1.7 million in 2022, then sank by 69.43% to $516000.0 in 2023, then advanced by 22.67% to $633000.0 in 2024, then decreased by 23.38% to $485000.0 in 2025.
- The last three Accounts Payables figures came in at $485000.0 (Q4 2025), $194000.0 (Q3 2025), and $378000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Chemomab Therapeutics | 13.33 Mn | 2.96 Mn | - | 485,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 485,000.00 |
| Sep 30, 2025 | 194,000.00 |
| Jun 30, 2025 | 378,000.00 |
| Mar 31, 2025 | 490,000.00 |
| Dec 31, 2024 | 633,000.00 |
| Sep 30, 2024 | 386,000.00 |
| Jun 30, 2024 | 1.11 Mn |
| Mar 31, 2024 | 527,000.00 |
| Dec 31, 2023 | 516,000.00 |
| Sep 30, 2023 | 731,000.00 |
| Jun 30, 2023 | 2.35 Mn |
| Mar 31, 2023 | 2.22 Mn |
| Dec 31, 2022 | 1.69 Mn |
| Sep 30, 2022 | 1.25 Mn |
| Jun 30, 2022 | 1.43 Mn |
| Mar 31, 2022 | 1.49 Mn |
| Dec 31, 2021 | 1.34 Mn |
| Sep 30, 2021 | 481,000.00 |
| Jun 30, 2021 | 472,000.00 |
| Mar 31, 2021 | 2.08 Mn |